Prolight publishes information document in connection with rights issue of shares
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. Prolight […]
The future of Point of Care Analysis – Right Here, Right Now
Prolight Diagnostics has developed a breakthrough point-of-care system that delivers reliable test results in 10 minutes or less, right at the patient´s side. Driving efficiency and accelerating time to clinical decision. Watch the video (https://youtu.be/WVNC8vKRdWA) to discover why our proprietary, patent-protected technology is at the heart of the next major shift in healthcare. For further information, please […]
Prolight announces additional subscription commitments and a lock-up commitment for upcoming rights issue of shares
Prolight Diagnostics (“Prolight” or the “Company”) hereby announces that additional existing shareholders and external investors have submitted subscription commitments totaling 2.9 MSEK for the upcoming rights issue of shares (the “Rights Issue”) that Prolight resolved on, subject to approval by the subsequent extraordinary general meeting, on May 21, 2025. Including these new subscription commitments, the […]
Biostock publishes article about the positive pre-clinical results and coming milestone for Prolight Diagnostics in Q2
Prolight’s CSO reflects on positive pre-clinical results and looks ahead to the next key milestone in Q2: Read the article here: https://biostock.se/2025/05/prolights-cso-reflects-on-positive-pre-clinical-results-and-looks-ahead-to-key-milestone-in-q2/ For further information, please contact:Ulf Bladin, CEOE-mail: info@prolightdx.comPhone: +46 73 582 39 87Company website: www.prolightdx.com About UsProlight Diagnostics AB develops innovative Point-of-Care (POC) systems. These are small, portable instruments and disposable cartridges for performing […]
Emergers publishes updated analysis about Prolight Diagnostics
Emergers publishes updated analysis about Prolight DIagnostics with the title: ”Gearing up for commercialisation with strong insider backing”. Among others, the article describes ”Strong insider commitment signals confidence” and that Prolight is ”Well-positioned for strategic partnering in 2025” Read the article here: https://www.emergers.se/prolight-j25/ For further information, please contact:Ulf Bladin, CEOE-mail: info@prolightdx.comPhone: +46 73 582 39 87Company website: […]
NOTICE OF EXTRAORDINARY GENERAL MEETING IN PROLIGHT DIAGNOSTICS AB (PUBL)
The shareholders in Prolight Diagnostics AB (publ), reg. no. 556570-9499, (the ”Company”) are hereby convened to the extraordinary general meeting to be held on Tuesday 10 June 2025 at 10 a.m. at the Company’s office, Gasverksgatan 3 A, 222 29 Lund, Sweden. Notification etc.Shareholders who wish to participate in the extraordinary general meeting must:– be […]
Prolight has resolved on a rights issue of shares to complete the development of the Point of Care system Psyros™ and reach commercialisation
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. The […]
Prolight receives new MicroFlex patent approval in the US
Prolight announces today that the US Patent and Trademark Office (USPTO), pursuant to the notice of allowance issued on March 26, has granted Prolight a patent for the analytical unit and reaction chamber for the company’s point-of-care analysis system, MicroFlex, which is being developed by Prolight’s partner TTP (The Technology Partnership plc). This patent complements the […]
Study highlights speed of biomarker integration on Psyros POC platform
A collaborative research project between Prolight and St Thomas’ Hospital has demonstrated how quickly a cardiac biomarker assay for cMyC, can be transferred onto the Psyros™ point-of-care (POC) system. The study underscores the platform’s potential and its broader diagnostic applications beyond high-sensitive troponin. As part of Prolight’s on-going relationship with St Thomas’ Hospital, the Psyros™ […]
Prolight announces positive pre-clinical data
Prolight Diagnostics today announces positive results from the company’s pre-clinical validation study using plasma biobank samples. The results demonstrate that Prolight is on track to deliver its high-sensitivity troponin assay on the Psyros™ single-molecule-counting system. “The study results are highly encouraging and affirm the performance underlying the Psyros technology. Our system demonstrated very good clinical sensitivity […]
